NEKTAR THERAPEUTICS
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $NKTR in the last 7 days.
No SEC Form 4 filings for $NKTR in the last 30 days.
See all $NKTR insider activity →Nektar Therapeutics claims Eli Lilly & Co. may owe it nearly $1 billion in damages for allegedly breaching their Rezpeg deal, according to testimony in a California federal court. The amount is based on Nektar's expert's calculation of lost profits and other factors.
Rezpegaldesleukin, a drug developed by Nektar Therapeutics, significantly reduced disease severity in moderate-to-severe atopic dermatitis patients in a phase 2b trial. All doses showed improved EASI scores and secondary endpoints compared to placebo. The treatment increased regulatory T cells and reduced key AD biomarkers, with common side effects including injection-site reactions. The study was funded by Nektar Therapeutics, and some authors have financial ties to the company.
Nektar Therapeutics (NKTR) stock is in focus after positive Phase 2b data for rezpegaldesleukin in The Lancet. The stock is up 67% YTD but trades 50% below the average analyst target of $144.40. NKTR has a robust cash position and faces risks like ongoing losses and reliance on trial outcomes.
Recent NKTR coverage spans earnings, technology and regulation.
Positive news for NKTR as it may receive a large settlement.
Positive trial data may boost NKTR's valuation and spark interest in its Treg‑targeting pipeline.
Positive trial results could lift NKTR toward its $144 fair value target.
Equity dilution from the grant may modestly pressure the share price, but signals hiring and pipeline investment.
The disclosed cash runway and higher spending guidance increase short‑term dilution risk but support long‑term Phase 3 programs.
AlphAI scores every news story that mentions NKTR with an AI model for sentiment and relevance, and aggregates insider trades from NEKTAR THERAPEUTICS's SEC EDGAR Form 4 filings. Figures refresh continuously.
Nektar Therapeutics claims Eli Lilly & Co. may owe it nearly $1 billion in damages for allegedly breaching their Rezpeg deal, according to testimony in a California federal court. The amount is based on Nektar's expert's calculation of lost profits and other factors.
2 min readRezpegaldesleukin, a drug developed by Nektar Therapeutics, significantly reduced disease severity in moderate-to-severe atopic dermatitis patients in a phase 2b trial. All doses showed improved EASI scores and secondary endpoints compared to placebo. The treatment increased regulatory T cells and reduced key AD biomarkers, with common side effects including injection-site reactions. The study was funded by Nektar Therapeutics, and some authors have financial ties to the company.
2 min readNektar Therapeutics (NKTR) stock is in focus after positive Phase 2b data for rezpegaldesleukin in The Lancet. The stock is up 67% YTD but trades 50% below the average analyst target of $144.40. NKTR has a robust cash position and faces risks like ongoing losses and reliance on trial outcomes.
3 min readNektar Therapeutics (NKTR) granted 25,200 stock options and 5,000 RSUs to new employees under its 2025 Inducement Plan. Options have an exercise price of $74.53, vest over 4 years. Nektar focuses on autoimmune and inflammatory disease treatments, with lead candidate rezpegaldesleukin in clinical trials.
1 min readNektar Therapeutics (NKTR) reported Q2 earnings, highlighting a $1.02B cash balance and Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. The company expects top-line data in mid-2028 and a potential Biologics License Application submission in 2029. NKTR's operating loss widened to $42.3M, with R&D spending expected to increase. The company raised $373.8M in April 2026 to fund operations.
3 min readNektar Therapeutics reported Q2 2026 earnings with noncash royalty revenue of $10.1M, a net loss of $40.6M, and cash/investments of $1.02B. The company initiated Phase 3 trials for rezpegaldesleukin and updated full-year guidance, including revenue of $40M-$45M and end-of-year cash of $815M-$840M. Management expects a cash runway into Q3 2028, supported by a recent public offering.
3 min readU.S. retail sales fell 0.6% in July, per the Department of Commerce, versus a Zacks breakeven; June was 0.2%. Ex-auto retail sales declined 0.3%. Earnings: Applied Materials (AMAT) adjusted EPS $3.50 vs $3.38 est, revenue $9.12B vs +1.31% beat; Nektar (NKTR) adjusted loss $1.23 vs -$2.06 est, revenue $10.13M miss; StoneCo (STNE) EPS $0.47 vs $0.46 est, revenue $709.88M miss.
4 min readU.S. stock futures were mixed as the S&P 500 headed for a winning week after a new all-time high. Retail sales fell 0.6% in July, though were up 5% year over year, per the Commerce Department. Earnings: AMAT adjusted EPS $3.50 (vs $3.38 est) on $9.12B revenue; NKTR adjusted loss $1.23 (vs $2.06 est) on $10.13M revenue; STNE adjusted EPS $0.47 (vs $0.46 est) on $709.9M revenue.
5 min readNektar Therapeutics (Nasdaq: NKTR) reported Q2 2026 results. Cash and marketable securities were $1,023.4M at June 30, 2026. Revenue was $10.1M vs $11.2M a year earlier. Operating costs were $52.5M and net loss was $40.6M ($1.23/share). Company said Phase 3 ZENITH AD trials began and cash runway extends into Q3 2028.
7 min readNEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nektar Therapeutics Announces Second Quarter 2026 Financial Results SAN FRANCISCO, Aug 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial r
6 min read
